Kanda Sangthongpitag
Overview
Explore the profile of Kanda Sangthongpitag including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
323
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cherian J, Nacro K, Poh Z, Guo S, Jeyaraj D, Wong Y, et al.
J Med Chem
. 2016 Mar;
59(7):3063-78.
PMID: 27011159
Clinically used BCR-ABL1 inhibitors for the treatment of chronic myeloid leukemia do not eliminate leukemic stem cells (LSC). It has been shown that MNK1 and 2 inhibitors prevent phosphorylation of...
12.
Duraiswamy A, Lee M, Madan B, Ang S, Tan E, Cheong W, et al.
J Med Chem
. 2015 Jun;
58(15):5889-99.
PMID: 26110200
Wnt proteins regulate various cellular functions and serve distinct roles in normal development throughout life. Wnt signaling is dysregulated in various diseases including cancers. Porcupine (PORCN) is a membrane-bound O-acyltransferase...
13.
Zhang W, Neo S, Gunaratne J, Poulsen A, Boping L, Ong E, et al.
Cell Signal
. 2014 Dec;
27(3):436-42.
PMID: 25530215
The high proliferation rate of cancer cells, together with environmental factors such as hypoxia and nutrient deprivation can cause Endoplasmic Reticulum (ER) stress. The protein kinase PERK is an essential...
14.
Choong M, Pecquet C, Pendharkar V, Diaconu C, Yong J, Tai S, et al.
J Cell Mol Med
. 2013 Nov;
17(11):1397-409.
PMID: 24251790
Current JAK2 inhibitors used for myeloproliferative neoplasms (MPN) treatment are not specific enough to selectively suppress aberrant JAK2 signalling and preserve physiological JAK2 signalling. We tested whether combining a JAK2...
15.
Larsson E, Jansson A, Ng F, Then S, Panicker R, Liu B, et al.
J Med Chem
. 2013 May;
56(11):4497-508.
PMID: 23672613
Tankyrases constitute potential drug targets for cancer and myelin-degrading diseases. We have applied a structure- and biophysics-driven fragment-based ligand design strategy to discover a novel family of potent inhibitors for...
16.
De Robertis A, Valensin S, Rossi M, Tunici P, Verani M, De Rosa A, et al.
Mol Cancer Ther
. 2013 Apr;
12(7):1180-9.
PMID: 23619303
Glioblastoma multiforme (GBM) is the most common and prognostically unfavorable form of brain tumor. The aggressive and highly invasive phenotype of these tumors makes them among the most anatomically damaging...
17.
Jayaraman R, Pilla Reddy V, Pasha M, Wang H, Sangthongpitag K, Yeo P, et al.
Drug Metab Dispos
. 2011 Aug;
39(12):2219-32.
PMID: 21873472
The preclinical absorption, distribution, metabolism, and excretion (ADME) properties of Pracinostat [(2E)-3-[2-butyl-1-[2-(diethylamino) ethyl]-1H-benzimidazol-5-yl]-N-hydroxyarylamide hydrochloride; SB939], an orally active histone deacetylase inhibitor, were characterized and its human pharmacokinetics (PK) was predicted...
18.
Wang H, Yu N, Chen D, Lee K, Lye P, Chang J, et al.
J Med Chem
. 2011 Jun;
54(13):4694-720.
PMID: 21634430
A series of 3-(1,2-disubstituted-1H-benzimidazol-5-yl)-N-hydroxyacrylamides (1) were designed and synthesized as HDAC inhibitors. Extensive SARs have been established for in vitro potency (HDAC1 enzyme and COLO 205 cellular IC(50)), liver microsomal...
19.
Wang H, Lim Z, Zhou Y, Ng M, Lu T, Lee K, et al.
Bioorg Med Chem Lett
. 2010 May;
20(11):3314-21.
PMID: 20451378
Thirty-six novel acylurea connected straight chain hydroxamates were designed and synthesized. Structure-activity relationships (SAR) were established for the length of linear chain linker and substitutions on the benzoylurea group. Compounds...
20.
Novotny-Diermayr V, Sangthongpitag K, Hu C, Wu X, Sausgruber N, Yeo P, et al.
Mol Cancer Ther
. 2010 Mar;
9(3):642-52.
PMID: 20197387
Although clinical responses in liquid tumors and certain lymphomas have been reported, the clinical efficacy of histone deacetylase inhibitors in solid tumors has been limited. This may be in part...